Efficacy and Tolerability of Donepezil in Vascular Dementia

Background and Purpose—Clinical observations suggest that patients with vascular dementia (VaD) may benefit from treatment with cholinesterase inhibitors. This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD. Methods—Patients (n 603; mean age, 73.9 years; 55.2% men) with probable (70.5%) or possible (29.5%) VaD, according to criteria of the National Institute of Neurological Disorders and Stroke (NINDS) and the Association Internationale pour la Recherche et l’Enseignement en Neurosciences (AIREN), were randomized to 24 weeks of treatment with donepezil 5 mg/d (n 198), donepezil 10 mg/d (5 mg/d for first 28 days; n 206), or placebo (n 199). Analyses were based on the intent-to-treat population. Results—At week 24, both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer’s Disease Assessment Scale–cognitive subscale (mean change from baseline score effect size: donepezil 5 mg/d, 1.90; P 0.001; donepezil 10 mg/d, 2.33; P 0.001). Significant improvements in patients’ global function were seen versus placebo at week 24 (observed cases), on the Clinician’s Interview-Based Impression of Change–Plus version only for patients on donepezil 5 mg/d (P 0.014), and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d (P 0.007). Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer’s Disease Functional Assessment and Change Scale (mean change from baseline score effect size at week 24: donepezil 5 mg/d, 1.31, P 0.02; donepezil 10 mg/d, 1.31, P 0.02). Donepezil was well tolerated. Withdrawal rates due to adverse events were relatively low (placebo, 11.1%; donepezil 5 mg/d, 11.1%; donepezil 10 mg/d, 21.8%; P 0.005 versus placebo). Conclusions—These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition. (Stroke. 2003;34:2323-2332.)

[1]  J. Morris,et al.  Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change , 2017 .

[2]  S. Salloway,et al.  Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial , 2003, Stroke.

[3]  G. Small,et al.  An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. , 2003, Clinical therapeutics.

[4]  R. Harvey,et al.  Propentofylline for dementia. , 2003, The Cochrane database of systematic reviews.

[5]  P. Knipschild,et al.  Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. , 2003, Journal of clinical epidemiology.

[6]  P. Whitehouse,et al.  Vinpocetine for cognitive impairment and dementia. , 2003, The Cochrane database of systematic reviews.

[7]  C. Callahan,et al.  The Efficacy of Pentoxifylline in the Treatment of Vascular Dementia: A Systematic Review , 2003, Alzheimer disease and associated disorders.

[8]  H. Geerts,et al.  The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease , 2002, Journal of the Neurological Sciences.

[9]  Rita Moretti,et al.  Rivastigmine in subcortical vascular dementia An open 22-month study , 2002, Journal of the Neurological Sciences.

[10]  R. Kalaria.  Similarities between Alzheimer's disease and vascular dementia , 2002, Journal of the Neurological Sciences.

[11]  R. Pratt.  Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia , 2002, Journal of the Neurological Sciences.

[12]  G. Wilcock,et al.  A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) , 2002, International clinical psychopharmacology.

[13]  Y. Stern,et al.  Mortality in patients with dementia after ischemic stroke , 2002, Neurology.

[14]  J. Birks,et al.  Nimodipine for primary degenerative, mixed and vascular dementia. , 2002, The Cochrane database of systematic reviews.

[15]  J. Orgogozo,et al.  Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300) , 2002, Stroke.

[16]  D. Royall,et al.  Alzheimer disease as a vascular disorder: nosological evidence. , 2002, Stroke.

[17]  G. Román.  Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. , 2002, The Medical clinics of North America.

[18]  Serge Gauthier,et al.  Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial , 2002, The Lancet.

[19]  L. Schneider.  Galantamine for vascular dementia: some answers, some questions , 2002, The Lancet.

[20]  Ronald A Cohen,et al.  Cognitive and motor impairments predict functional declines in patients with vascular dementia , 2002, International journal of geriatric psychiatry.

[21]  H. Möller,et al.  Naftidrofuryl in the treatment of vascular dementia , 2001, European Archives of Psychiatry and Clinical Neuroscience.

[22]  D. Leys,et al.  Poststroke dementia: Incidence and relationship to prestroke cognitive decline , 2001 .

[23]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[24]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[25]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[26]  M. Dubois,et al.  The Incidence of Vascular Dementia in Canada: A Comparison with Europe and East Asia , 2001, Neuroepidemiology.

[27]  I. McKeith,et al.  The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease , 2001, International journal of geriatric psychiatry.

[28]  H. Saito,et al.  Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. , 2000, Toxicology.

[29]  T. Erkinjuntti,et al.  Investigating the Natural Course and Treatment of Vascular Dementia and Alzheimer's Disease: Parallel Study Populations in Two Randomized, Placebo‐Controlled Trials , 2000, Annals of the New York Academy of Sciences.

[30]  D. Royall,et al.  Executive control function: a rational basis for the diagnosis of vascular dementia. , 1999, Alzheimer disease and associated disorders.

[31]  A. Korczyn,et al.  Denbufylline in Dementia: A Double-Blind Controlled Study , 1999, Dementia and Geriatric Cognitive Disorders.

[32]  H.-J. Möller,et al.  The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1 , 1999, Dementia and Geriatric Cognitive Disorders.

[33]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[34]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[35]  D. Cucinotta,et al.  Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results. , 1997, Thrombosis research.

[36]  B. Winblad,et al.  Cognitive changes in very old persons with dementia: the influence of demographic, psychometric, and biological variables. , 1997, Journal of clinical and experimental neuropsychology.

[37]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[38]  L. Murri,et al.  Posatirelin in the treatment of vascular dementia: a double‐blind multicentre study vs placebo , 1996, Acta neurologica Scandinavica.

[39]  H. Semlitsch,et al.  Nicergoline in senile dementia of alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study , 1995, Psychopharmacology.

[40]  K. Blennow,et al.  The neurochemistry of vascular dementia. , 1994, Dementia.

[41]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[42]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[43]  N. Lassen,et al.  Multi-infarct dementia. A cause of mental deterioration in the elderly. , 1974, Lancet.

[44]  H. Tohgi,et al.  Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia , 2005, Journal of Neural Transmission.

[45]  Anthony F Jorm.  Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[46]  Sandra E Black,et al.  Strategic involvement of cholinergic pathways and executive dysfunction: Does location of white matter signal hyperintensities matter? , 2003, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[47]  W. Herrmann,et al.  Therapeutic efficacy of vincamine in dementia. , 1996, Neuropsychobiology.